Prevention study expects first biomarker results by late 2016

GHR Foundation’s Health Initiative is dedicated the prevention of Alzheimer’s disease. The Foundation is targeting funding to improve some of the most important research efforts in the field, including Washington University’s DIAN-TU Study. This trial focuses on rapid testing of prevention therapies among families that are most likely to develop the disease.

Recently, DIAN-TU announced it has completed participant enrolment for the first stage of the trial. This enrolment milestone means the first biomarker results will be available at the end of 2016, with the final cognitive endpoint expected in late 2019. This first stage will determine the effects of two drugs targeting amyloid plaques, which are believed by some scientists to be the first step in the process leading to cognitive impairment.

 

Read more about the study here